Future Directions for Treatment of Ovarian Cancer

Olvimulogene nanivacirepvec virotherapy plus chemotherapy with or without bevacizumab produces a manageable safety profile in platinum-resistant or platinum-refractory ovarian cancer in the phase 2 VIRO-15 trial.

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

The antitumor activity of niraparib maintenance therapy in patients with advanced ovarian cancer remains unclear among those with measurable residual disease at baseline in the phase 3 PRIME study.

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Patients with folate receptor alpha (FRα)–high, platinum-resistant ovarian cancer experienced progression-free survival benefit following treatment with mirvetuximab soravtansine-gynx.

Maintenance bevacizumab plus durvalumab and olaparib appears to produce a progression-free survival benefit among those with HRD-negative advanced ovarian cancer in the phase 3 DUO-O trial.